BlossomHill Therapeutics, Inc. (BLSM)
| Market Cap | 593.87M |
| Revenue (ttm) | n/a |
| Net Income | -71.09M |
| EPS | -28.59 |
| Shares Out | 30.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,689 |
| Open | 19.10 |
| Previous Close | 18.99 |
| Day's Range | 18.84 - 19.91 |
| 52-Week Range | 15.25 - 20.61 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.00 (+59.96%) |
| Earnings Date | n/a |
About BLSM
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BLSM stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 59.96% from the latest price.
News
Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential
As previously reported, Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target BlossomHill’s “precision oncology” pipeline has potential to generate “s...
BlossomHill Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $36 price target
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Tr...
BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $32 price target
BlossomHill Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target
BlossomHill Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $35 price target BlossomHill is focused on the design and development of novel, proprie...
BlossomHill Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and $28 price target BlossomHill is a clinical-stage oncology company “leveraging management’s valuable know-ho...
BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA
BlossomHill Therapeutics (BLSM) announced that the FDA has granted fast track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor C...
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and d...
BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it raised $150 million in its U.S. IPO. Below the IPO Price The…
BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00
BlossomHill Therapeutics (BLSM) priced 9.375M shares at $16.00. The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00…
BlossomHill Therapeutics 9.375M share IPO priced at $16.00
The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00 range. JPMorgan, Leerink, Guggenheim, Lake Street and H.C.
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach...
BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00
JPMorgan, Leerink, Guggenheim, Lake Street and H.C. Wainwright are acting as joint book running managers for the offering.
Latigo, BlossomHill launch US IPOs as biotech listings rebound
Drug developers Latigo Biotherapeutics and BlossomHill Therapeutics launched their U.S. initial public offerings on Monday riding the wave of biotech listings.
Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO
BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BlossomHill Therapeutics IPO Registration Document (S-1)
BlossomHill Therapeutics has filed to go public with an IPO on the NASDAQ